Journals / İnönü Üniversitesi Tıp Fakültesi Dergisi / 2006 / Cilt: 13 - Sayı: 2

GnRH agonists and antagonists: Current aspects

GnRH agonistleri ve antagonistleri: Güncel yönleri

Pages
135–140
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the performance of agonists and antagonists during controlled ovarian hyperstimulation and clinical or ongoing pregnancy rates have been detailed with clinical studies and recent recommendations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ABSTRACT: GnRH agonists have been widely accepted in some clinical aspects such as symptomatic endometriosis or leimyomata.
📊
Key Findings & Data:Once the GnRH antagonists had been discovered which have been attributed to have no flare up effect with a lower ovarian hyperstimulation syndrome incidence and decrease in requirement of total exogenous gonadotrophin use, it is still controversial whether GnRH antagonists or agonists are more suitable for a optimum ovarian stimulation protocol.
💡
Conclusion & Impact:In this review, the performance of agonists and antagonists during controlled ovarian hyperstimulation and clinical or ongoing pregnancy rates have been detailed with clinical studies and recent recommendations.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

ABSTRACT: GnRH agonists have been widely accepted in some clinical aspects such as symptomatic endometriosis or leimyomata. Since assisted reproductive technologies have been appeared, GnRH agonists have expanded its clinical usage. Although the flare up effect of agonists has been noted, its application during controlled ovarian hyperstimulation in order to inhibit premature ovulation had been valid without an alternative medication for a long period. Once the GnRH antagonists had been discovered which have been attributed to have no flare up effect with a lower ovarian hyperstimulation syndrome incidence and decrease in requirement of total exogenous gonadotrophin use, it is still controversial whether GnRH antagonists or agonists are more suitable for a optimum ovarian stimulation protocol. In this review, the performance of agonists and antagonists during controlled ovarian hyperstimulation and clinical or ongoing pregnancy rates have been detailed with clinical studies and recent recommendations.

Özet

ÖZET: Semptomatik endometriosis ve leimyoma gibi sebeplerden dolayı zaten kullanılmakta olan GnRH agonistleri, yardımcı üreme tekniklerinin ortaya çıkmasıyla birlikte kendisine daha da geniş kullanım alanı bulmuştur. İlk uygulandığında mevcut hipofizer gonadotropinlerin hızlıca salınmasına bağlı ortaya çıkan alevlendirici (flare up) etkisi aslında istenmeyen bir yan etkisi olsa da erken spontan ovulasyonu baskılamak amacıyla yakın zamana kadar alternatifsiz olarak kullanılagelmiştir. Alevlendirici etkisinin olmadığı, ovaryan hiperstimülasyon sendromunun daha az izlendiği, toplam eksojen gonadotropin ihtiyacının daha düşük olduğu iddia edilen GnRH antagonistlerinin ortaya çıkması ile birlikte, klinisyenler arasında hangisinin genel yönleriyle daha uygun olduğu hakkında ki tartışmalar yapılan karşılaştırmalı çalışmalar ile halen devam etmektedir. Yapılan bu derlemede, mevcut klinik çalışmalar ve güncel bilgiler çerçevesinde, GnRH agonist ve antagonistleri gerek kontrollü ovaryan stimülasyon performansları, gerekse de gebelik oranları açısından detaylıca değerlendirilmektedir.

🔖

Cite This Article

GÜRGAN, T., BOZDAĞ, G., DEMİROL, A. (2022). GnRH agonists and antagonists: Current aspects. İnönü Üniversitesi Tıp Fakültesi Dergisi, Cilt: 13 - Sayı: 2, 135–140. https://ajindex.com/articles/548734

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. King JA, Millar RP. Evolutionary aspects of gonadotropin-releasing hormone and its receptor. Cell Mol Neurobiol 1995;15:5-23
  2. White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin- releasing hormone in humans. Proc Natl Acad Sci U S A 1998;95:305-9
  3. Grundker C, Gunthert AR, Millar RP, Emons G. Expression of gonadotropin- releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002;87:1427-30
  4. Tanriverdi F, Gonzalez-Martinez D, Silveira LF, Hu Y, Maccoll GS, Travers P, et al. Expression of gonadotropin-releasing hormone type-I (GnRH-I) and type-II (GnRH- II) in human peripheral blood mononuclear cells (PMBCs) and regulation of B- lymphoblastoid cell proliferation by GnRH-I and GnRH-II. Exp Clin Endocrinol Diabetes 2004;112:587-94
  5. Millar RP. GnRH II and type II GnRH receptors. Trends Endocrinol Metab 2003;14:35-43
  6. Loutradis D, Drakakis P, Kallianidis K, Bletsa R, Milingos S, Makris N, et al. The effect of the duration of GnRH-agonist down regulation before ovarian stimulation on the biological and clinical outcome after intracytoplasmic sperm injection. Eur J Obstet Gynecol Reprod Biol 1998;80:251-5
  7. Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F. GnRH antagonist- induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J 2005;52:131-7
  8. Malmusi S, La Marca A, Giulini S, Xella S, Tagliasacchi D, Marsella T, et al. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril 2005;84:402-6
  9. Hazum E, Koch Y, Liscovitch M, Amsterdam A. Intracellular pathways of receptor- bound GnRH agonist in pituitary gonadotropes. Cell Tissue Res 1985;239:3-8
  10. Schally AV, Nair RM, Redding TW, Arimura A. Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalami. J Biol Chem 1971;246:7230-6
  11. Hoshiai H. Current guidelines for treatment of endometriosis. The present status in Japan. Drugs Today (Barc) 2005;41 Suppl A:17-21
  12. Furui T, Imai A, Takagi A, Tamaya T, Takagi H, Matsunami K, et al. Differential efficacy of gonadotropin-releasing hormone (GnRH) agonist treatment on pedunculated and degenerated myomas: a retrospective study of 630 women. J Obstet Gynaecol 2000;20:504-6
  13. Stanhope R, T